Osteoporosis drug Prolia could reap sales of more than $500m by 2019, according to a report from Decision Resources.

The firm says that Amgen/GlaxoSmithKline’s Prolia, recently approved in the US and Europe, can expect high sales in the US, France, Germany, Italy, Spain, the UK and Japan.

Prolia’s success will rest on its twice yearly, subcutaneous delivery, which experts believe will improve patient compliance above other available agents such as the generic alendronate and Sanofi-Aventis/Warner Chilcott’s Actonel.

However, the report also warns that Prolia’s uptake in the mature osteoporosis drug market will be constrained by the increasing availability of generics, safety concerns and a comparatively high price.